drugset
drugset / Trial / NCT04806373

Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

NCT04806373 ↗

Phase 4 Completed 27 enrolled Memorial Healthcare System Genentech, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis versus Standard of care Talc therapy in patients with recurrent pleural effusion.

Timeline

Start
2021-06-15
Primary completion
2023-12-14
Completion
2023-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 4 mg Other
Background Talc Slurry Pleurodesis Unknown 5 g Other

Indications

No indication recorded.